Your browser doesn't support javascript.
loading
What is the evidence for the clinical value of SBRT in cancer of the cervix?
Yanez, Loreto; Ciudad, Ana M; Mehta, Minesh P; Marsiglia, Hugo.
Affiliation
  • Yanez L; Radiotherapy Dept., Fundación Arturo López Pérez, Santiago, Chile.
  • Ciudad AM; Radiotherapy Dept., Fundación Arturo López Pérez, Santiago, Chile.
  • Mehta MP; Miami Cancer Institute-Baptist Hospital, Miami, USA.
  • Marsiglia H; Radiotherapy Dept., Fundación Arturo López Pérez, Santiago, Chile.
Rep Pract Oncol Radiother ; 23(6): 574-579, 2018.
Article in En | MEDLINE | ID: mdl-30534021
AIM: The aim of this review is to describe and analyze indications and results of the use of SBRT in uterine cervix cancer, reviewing articles published from January 2010 up to August 2017, for any one of the four indications listed:1Patient refusal or anatomic impediments to interstitial or intracavitary brachytherapy (BCT), i.e. SBRT as an "alternative" for BCT;2Patients with voluminous tumors, or asymmetric tumors where BCT alone would not achieve curative doses, i.e. SBRT as a primary adjunct to BCT;3Pelvic and para aortic adenopathy where SBRT could be used as a boost, i.e. SBRT as a primary adjunct to external beam pelvic radiotherapy;4Small volume recurrences (postoperative or post radiotherapy), i.e. SBRT for salvage. BACKGROUND: Cervix cancer standard treatment involves pelvic irradiation and chemotherapy, recent advances in irradiation techniques might offer new possible approaches. MATERIAL AND METHODS: Systematic review of the English language literature about Cervix cancer, SBRT, published from January 2010 to January 2018 identified through a database search of PubMed, and Ovid MEDLINE, using pre-defined search phrases. RESULTS: The results in the literature, in general, demonstrate rather weak efficacy of SBRT. In this review, we did not find strong evidence to recommend routine SBRT as a primary treatment for cervico-uterine cancers, i.e. as a replacement for BCT; in highly selected cases it might be considered useful as salvage therapy for relapsed cervix cancer. CONCLUSION: The existing data to not warrant recommending SBRT for the definitive treatment of cervix cancer, but may have some value in the recurrent/relapsed setting.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rep Pract Oncol Radiother Year: 2018 Document type: Article Affiliation country: Chile Country of publication: Poland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rep Pract Oncol Radiother Year: 2018 Document type: Article Affiliation country: Chile Country of publication: Poland